top of page

Dmitry Kaminskiy Presents Biomarkers of Human Longevity Book to Prince Michael Von Liechtenstein


Dmitry Kaminskiy and Prince Michael of Liechtenstein and Founder of the International Institute of Longevity Joanna Bensz

During a three-day series of Longevity-themed events in Geneva, Zurich, and Basel, Deep Knowledge Group General Partner had occasion to meet with Prince Michael Von Liechtenstein, a member of the House of Liechtenstein and an heir to the Liechtensteiner throne.


Prince Michael also serves as Co-Founder of the International Institute of Longevity and Longevity Center, Chairman of the European Center of Austrian Economics Foundation Vaduz, Executive Chairman of Industrie- und Finanzkontor Ets. Vaduz (a leading trust company specializing in long-term and multi-generational preservation of wealth), and Founder and Chairman of Geopolitical Intelligence Services AG Vaduz.


During the meeting, Kaminskiy also presented Prince Michael with a gift: a complimentary copy of his newest book, Biomarkers of Human Longevity: Data Science for Accelerating Aging Research and R&D and The Critical Catalyst for Practical Human Longevity, Tangible Investment Decision Making and De-Risking, officially published in October 2021.


In the book, Dmitriy Kaminskiy urges major Longevity Industry decision-makers to adopt Biomarkers of Human Longevity as the fundamental market-ready tool and framework for industry stabilization, tangible decision-making, predictable forecasting of clinical trial outcomes, public market consistency, investment de-risking, reliable validation of Longevity technologies and therapies, and safer frameworks for formulating, adjusting, and validating personal Practical Longevity regimens. 


Its content and major forecasting are based on years of AI and data science-driven open-access and proprietary quantitative research, forecasting and deep analysis conducted by Deep Knowledge Group’s 10+ analytical subsidiaries to help major industry decision-makers on-board the practices and frameworks that are considered to be fundamentally necessary to maintain stable industry growth, bridge the Longevity Liquidity Gap, enable actual Practical Human Longevity, neutralize the vast-yet-unacknowledged translational gap from model organisms to humans, and accelerate the socially-inclusive delivery of Longevity’s real-world humanitarian impacts for citizens and national economies.


Meanwhile, Prince Michael von Liechtenstein is no stranger to many of the key messages and take-aways from the book, including the need for Longevity-progressive governments to begin supporting and developing the critical technological and policy infrastructure required to accelerate the industrialization of Precision Medicine, and to facilitate the optimization of population-level Healthy Longevity. Indeed, Prince Michael is one of the key advocates for a more coordinated, direct and sophisticated approach to Longevity Policy and Governance in Liechtenstein and the surrounding Alpine European region.


As described more comprehensively in his upcoming book, Longevity Politics: Longevity Technocracy, Modern Approaches to Policy, Governance, and National Industrial Strategies, and Longevity as the New Political Priority of the 21st Century, Dmitry Kaminskiy notes that Liechtenstein already has a number of raw strengths and resources that, if properly and synergistically assembled, could satisfy two of the most important prerequisites for relevant, sophisticated and modern Longevity Policy and Governance: governmental recognition of the challenge of aging and the massive socioeconomic opportunity of Longevity, on the one hand, and efficient strategy execution on the other. 


The principality’s foremost strength lies in public statements indicating the commitment of Prince Michael von Liechtenstein, a key political figure of the country, to ensure that Liechtenstein has an integrated approach to National Longevity Development and Longevity Industrialization that unites the pillars of preventive healthcare, geroscience R&D, and Longevity Economy. More on this matter can be read in Prince Michael’s essay, 'Geopolitical significance of the Longevity sector'.


Liechtenstein is a hub for Preventive Medicine, and its medical system strives to prevent diseases. Precision Health Clinics are the subsidiaries of the International Institute of Longevity founded by Prince Michael von Liechtenstein. One of those clinics is in Liechtenstein itself while the other one is in Poland. While this does not amount to a formal, government-led National Longevity Development Plan per se, it is a large step in the right direction, putting the country on strong footing (especially when combined with its strong finance and preventive medicine sectors) to formulate and execute a strong and relevant National Longevity Strategy, provided that it can secure formal commitment and prioritization from its government.


Meanwhile, Liechtenstein’s specific strengths which could be leveraged to turn it into an effective Longevity Hub - including its financial progressiveness and wealth (high GDP per capita) and its geopolitical flexibility as a comparatively small state, combined to its physical proximity to other technological and biomedical hubs (including Switzerland and other nearby Precision Medicine hubs in Alpine Europe) - was noted in an April 2021 essay by Dmitry Kaminskiy, 'Health as the New Wealth: How the Asset Class of Longevity Will Become the New Norm for Citizen and Corporate Migration', published by Henley and Partners (the global leader in residence and citizenship planning) alongside essays by Dr. Parag Khanna (author of The Future is Asian) and other influential thought-leaders.


The venue for Dmitry Kaminskiy and Prince Michael von Liechtenstein’s meeting was the ‘Longevity Meets Basel', a conference by the prestigious Weizman Institute of Science (WYEN), hosted by Wyen Board Member Dr. Sanja Baumann-Tomovska.


Dmitry Kaminskiy delivers his presentation at ‘Longevity Meets Basel’ Conference


Dr. Sanja Baumann-Tomovska and Dmitry Kaminskiy as Moderators of the Panel Discussion (Aging: The Longevity Dividend)

During the conference, Dmitry Kaminskiy delivered a keynote presentation entitled ‘Biomarkers of Human Longevity as the Critical Catalyst for Tangible Investment Decision-Making and De-Risking’, and сhaired a Panel Discussion (Aging: The Longevity Dividend), featuring a number of Longevity investment, policy and biomedicine firms including Joanna Bensz (Co-Founder and CEO, Longevity Center; CEO, International Institute of Longevity), Leo Grunstein (Founder and CEO of Spiden AG, Chairman of Venture Builder LG Capital AG), Dr. Yaron Daniely (Partner, Amoon), Dr. Tobias Reichmuth (Founding Partner, Maximon), Garri Zmudze (Founding Partner, Longe-VC), and Dr. Matthias Steger (Co-Founder and CEO, Rejuveron Life Sciences).

IMG_3519-2 (1).jpg

Dmitry Kaminskiy as a Speaker at the WYEN Conference ‘Longevity Meets Basel‘

Meanwhile, the Basel conference was situated within the larger context of a dedicated trip to Switzerland made by several Deep Knowledge Group Partners and Senior Executives, which included earlier in the week two  invitation-only Longevity Finance and Investment-themed enents organized by Deep Knowledge Group in order to  engage key Swiss stakeholders (investors, financial executives and government officials) on the prospects for transforming Switzerland into the world’s first full-scope Longevity Finance, Industry, Biomedicine and Policy Hub (Swiss Longevity Valley). A more comprehensive summary of those events, as well as key take-aways form the entire series of events, can be found here:

IMG_4184_Books (1).png
bottom of page